NHS access to Wegovy is through specialist weight management services, based on obesity criteria (BMI of 35 or higher, plus at least one weight-related condition)
Do not put it in your household trash
Agonists are under intense study, as different kinds of hormone agonists may be useful for a variety of medical processes, including the treatment of prostate cancer, endometriosis, and more
Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027
Using without a prescription, purchasing without research, and careless administration make compounded semaglutide unsafe
Skendros P, Papagoras C, Lefaki I, et al